If you have been reading about Toll-like receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
== Dorsopathies (720–724) == 720 Ankylosing spondylitis and other inflammatory spondylopathies 720.0 Ankylosing spondylitis 720.1 Spinal enthesopathy 720.2 Sacroiliitis 721 Spondylosis and allied disorders 721.0 Cervical spondylosis w/o myelopathy 721.1 Cervical spondylosis, w/myelopathy 721.2 Thoracic spondylosis w/o myelopathy 721.3 Lumbosacral spondylosis w/o myelopathy 721.4 Thoracic or lumbar spondylosis w/ myelopathy 721.5 Kissing spine 721.6 Ankylosing vertebral hyperostosis 721.7 Traumatic spondylopathy 722 Intervertebral disc disorders 722.0 Displacement cervical intervertebral disc 722.1 Lumbar disc displacement w/o myelopathy 722.2 Degeneration of intervertebral disc site unspecified 722.3 Schmorl's nodes 722.4 Degenerative disc disease, cervical 722.5 Degeneration of thoracic or lumbar intervertebral disc 722.51 Degenerative disc disease, thoracic 722.52 Degenerative disc disease, lumbar 722.6 Degeneration of intervertebral disc, site unspecified Degenerative disc disease 722.7 Intervertebral disc disorder with myelopathy 722.8 Postlaminectomy syndrome 723 Other disorders of cervical region 723.0 Spinal stenosis in cervical region 723.1 Cervicalgia 723.2 Cervicocranial syndrome 723.3 Cervicobrachial syndrome (diffuse) 723.4 Brachial neuritis or radiculitis nos 723.5 Torticollis unspecified 723.6 Panniculitis specified as affecting neck 723.7 Ossification of posterior longitudinal ligament in cervical region 724 Other and unspecified disorders of back 724.0 Spinal stenosis, other than cervical 724.1 Pain in thoracic spine 724.2 Lumbago 724.3 Sciatica 724.4 Back pain w/ radiation, unspec. 724.5 Backache, unspecified 724.6 Disorders of sacrum 724.7 Disorders of coccyx 724.79 Coccygodynia 724.8 Other symptoms referable to back
50% androgens 30% mixed 10% steroids 10% hormone-inactive The average time from the onset of symptoms to diagnosis is six months. Approximately 70% of tumors can be completely removed surgically. The current state of research is considered insufficient. The few available comparisons between adrenocortical carcinomas in adults and children indicate significant differences. Therefore, findings obtained so far in adults cannot be readily applied to children. To close these knowledge gaps and to be able to determine suitable therapies for children, a better molecular biological understanding of the prognosis and tumor biology of adrenocortical tumors in children is needed. Currently, the main research questions are:
=== Rum trading === Grose also relaxed Phillip's prohibition on trading of rum, sometimes a generic term for any form of distilled beverage, usually made from wheat, commonly from Bengal. The colony, like many British territories at the time, was short of coins, and rum soon became the medium of trade. The officers of the Corps were able to use their position and wealth to buy all the imported rum and then exchange it for goods and labour at very favourable rates, earning the Corps the nickname "The Rum Corps". By 1793 stills were being imported and grain was being used to make rum, exacerbating the shortage of grain. Due to poor health Grose returned to England in December 1794 and Captain William Paterson assumed temporary command until a permanent replacement, Governor John Hunter, arrived in September 1795. Paterson had obtained his commission with the backing of Sir Joseph Banks because he was interested in natural history and would explore and collect samples for Banks and the Royal Society. Governor Hunter attempted unsuccessfully to use the troops of the Corps to guard imported rum and stop the officers from buying it up. Attempts to stop the importation were also thwarted by the failure of other governments to co-operate and by the Corps' officers chartering of a Danish ship to bring in a large shipment of rum from India. Hunter also tried to start up a public store with goods from England to provide competition and stabilise the price of goods, but Hunter was not a good businessman and supplies were too erratic.
Sources: en.wikipedia.org
== L == LALLS – Low-angle laser light scattering LC-MS – Liquid chromatography-mass spectrometry LEED – Low-energy electron diffraction LEEM – Low-energy electron microscopy LEIS – Low-energy ion scattering LIBS – Laser induced breakdown spectroscopy LOES – Laser optical emission spectroscopy LS – Light (Raman) scattering
=== Animals === For mice, the dose at which acute toxicity occurs for intravenous administration is 40 mg/kg and for subcutaneous injection (injection in the layer of skin directly below the dermis and epidermis) this is 380 mg/kg. The lethal dose of dimethocaine for a mouse is 0.3 g per kilogram body weight. An abdominal constriction test was performed in mice, using doses of 5, 10, and 20 mg/kg of dimethocaine which were administered subcutaneously. This test showed induced dose-dependent antinociceptive responses, which are processes that block detection of a painful or injurious stimulus by sensory neurons. Impairment of memory processes was found to be a toxic effect in the elevated plus-maze test in mice.
It could possibly be extended to 10 days and prevent substantial cell damage by low temperature preservation methods. On the same day, a separate study reports new cryoprotectant solvents, tested with cells, that could preserve organs by the latter methods for much longer with substantially reduced damage.
Sources: en.wikipedia.org
=== Full scan MS === When collecting data in the full scan mode, a target range of mass fragments is determined and put into the instrument's method. An example of a typical broad range of mass fragments to monitor would be m/z 50 to m/z 400. The determination of what range to use is largely dictated by what one anticipates being in the sample while being cognizant of the solvent and other possible interferences. A MS should not be set to look for mass fragments too low or else one may detect air (found as m/z 28 due to nitrogen), carbon dioxide (m/z 44) or other possible interference. Additionally if one is to use a large scan range then sensitivity of the instrument is decreased due to performing fewer scans per second since each scan will have to detect a wide range of mass fragments. Full scan is useful in determining unknown compounds in a sample. It provides more information than SIM when it comes to confirming or resolving compounds in a sample. During instrument method development it may be common to first analyze test solutions in full scan mode to determine the retention time and the mass fragment fingerprint before moving to a SIM instrument method.
== Related preservation methods == Other methods have been in place for thousands of years to halt the decomposition of the body. Mummification used by the ancient Egyptians is a widely known method which involves the removal of body fluid and wrapping the body in linens. Prior to mummification, Egyptians would lay the body in a shallow pit in the desert and allow the sun to dehydrate the body. Formalin, an important solution to body preservation, was introduced in 1896 to help with body preservation. Soon to follow formalin, color-preserving embalming solutions were developed to preserve lifelike color and flexibility to aid in the study of the body. Paraffin impregnation was introduced in 1925, and the embedding of organs in plastic was developed in the 1960s. Body preservation methods current to the 21st century are cryopreservation, which involves the cooling of the body to very low temperatures to preserve the body tissues, plastination, and embalming. Other methods used in modern times include the Silicone S 10 Standard Procedure, the Cor-Tech Room temperature procedure, the Epoxy E 12 procedure, and the Polyester P 35 (P 40) procedure. The Silicone S 10 is the procedure most often used in plastination and creates opaque, natural-looking specimen., Dow Corning Corporation's Cor-Tech Room Temperature Procedure is designed to allow plastination of specimen at room temperature to various degrees of flexibility using three combinations of polymer, crosslinker, and catalyst.
== Terminology == The name used until 2026, polycystic ovary syndrome (PCOS), derived from a typical finding on medical images called "polycystic ovary morphology". A polycystic ovary has an abnormally large number of developing follicles, looking like many small cysts. There were various objections to the name polycystic ovary syndrome: the "cysts" are not truly cysts, but arrested follicles. Having many follicles in the ovaries is also not unique to PMOS, and is often seen in women without PMOS, particularly adolescents. Furthermore, the name implied that PMOS is a gynecological condition only, rather than a metabolic and endocrine condition. Other previous names for PMOS were Stein–Leventhal syndrome and polycystic ovary disease. Suggested names included hyperandrogenic (chronic) anovulation, estrogenic ovulatory dysfunction or functional female hyperandrogenism. For specific subgroups, suggested names included multi-follicular ovarian disorder for those with polycystic ovary morphology, and metabolic hyperandrogenic syndrome for those meeting the NIH PMOS criteria. Following discussions among clinicians and people with PCOS, a majority of whom were in favour of renaming the condition, a survey was launched to find a new name. In 2026, an article by Helena Teede and others in The Lancet described the "multistep global consensus process" through which clinicians agreed to rename the condition "polyendocrine metabolic ovarian syndrome" (PMOS).
Progesterone levels in the blood were found to be lower in those who had higher weight and higher BMI among those who became pregnant through in vitro fertilization. Current data shows that micronized progesterone, which is chemically identical to the progesterone produced in the human body, in combination with estrogen in menopausal hormone therapy does not seem to have significant effects on venous thromboembolism (blood clots in veins) and ischemic stroke (lack of blood flow to the brain due to blockage of a blood vessel that supplies the brain). However, more studies need to be conducted to see whether or not micronized progesterone alone or in combined menopausal hormone therapy changes the risk of myocardial infarctions (heart attacks). There have not been any studies done yet on the effects of micronized progesterone on hair loss due to menopause. Despite suggestions for using hormone therapy to prevent loss of muscle mass in post-menopausal individuals (age 50+), menopausal hormone therapy involving either estrogen alone, or estrogen and progesterone combined, has not been found to preserve muscle mass. Menopausal hormone therapy also does not result in body weight reduction, BMI reduction, or change in glucose metabolism.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。